1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11
2 Ovarian Cancer Therapeutics - Disease Overview 16
2.1 Overview 16
2.1.1 Types of Ovarian Cancer 16
2.2 Staging and Treatment of Ovarian Cancer 17
2.2.1 Stage I 21
2.2.2 Stage IA 21
2.2.3 Stage IB 21
2.2.4 Stage IC 21
2.2.5 Stage II 21
2.2.6 Stage IIA 21
2.2.7 Stage IIB 21
2.2.8 Stage IIC 21
2.2.9 Stage III 22
2.2.10 Stage IIIA 22
2.2.11 Stage IIIB 22
2.2.12 Stage IV 22
2.3 Epidemiology 22
2.4 Etiology 22
2.5 Symptoms 23
2.6 Risk Factors 23
2.7 Diagnosis 24
2.7.1 Physical Examination 24
2.7.2 Blood Tests 24
2.7.3 Human Chorionic Gonadotropin (hCG) Test 26
2.7.4 Ultrasound and CT Scans 26
2.7.5 Biopsy 26
2.8 Pathology 27
2.8.1 Grading 27
2.9 Prognosis 27
2.10 Treatment 28
2.10.1 Surgery 28
2.10.2 Chemotherapy 29
2.10.3 Radiation Therapy 29
2.11 Treatment Options by Stage 29
2.11.1 Stage IA 29
2.11.2 Stage IB 29
2.11.3 Stage IC 30
2.11.4 Stage IIA 30
2.11.5 Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV 30
2.11.6 Treatment Follow-Up 30
2.12 Chemotherapy Regimens 32
2.13 GlobalData In-Depth Report Guidance 33
3 Ovarian Cancer Therapeutics - Market Characterization 34
3.1 Global 34
3.1.1 Market Size 34
3.1.2 Drivers and Restraints 42
3.1.3 Forecasts 45
3.1.4 Drug Sales 54
3.2 The US 56
3.2.1 Market Size 56
3.2.2 Drivers and Restraints 63
3.2.3 Forecasts 66
3.2.4 Drug Sales 73
3.2.5 Pricing and Reimbursements 75
3.3 The UK 76
3.3.1 Market Size 76
3.3.2 Drivers and Restraints 84
3.3.3 Forecasts 87
3.3.4 Drug Sales 96
3.3.5 Pricing and Reimbursements 98
3.4 Germany 99
3.4.1 Market Size 99
3.4.2 Drivers and Restraints 107
3.4.3 Forecasts 110
3.4.4 Drug Sales 119
3.4.5 Pricing and Reimbursements 121
3.5 France 122
3.5.1 Market Size 122
3.5.2 Drivers and Restraints 130
3.5.3 Forecasts 132
3.5.4 Drug Sales 141
3.5.5 Pricing and Reimbursements 143
3.6 Italy 144
3.6.1 Market Size 144
3.6.2 Drivers and Restraints 152
3.6.3 Forecasts 155
3.6.4 Drug Sales 164
3.6.5 Pricing and Reimbursements 166
3.7 Spain 167
3.7.1 Market Size 167
3.7.2 Drivers and Restraints 175
3.7.3 Forecasts 178
3.7.4 Drug Sales 187
3.7.5 Pricing and Reimbursements 189
3.8 Japan 190
3.8.1 Market Size 190
3.8.2 Drivers and Restraints 198
3.8.3 Forecasts 201
3.8.4 Drug Sales 210
3.8.5 Pricing and Reimbursements 212
3.9 Brazil 213
3.9.1 Market Size 213
3.9.2 Patient Volume 216
3.9.3 Drivers and Restraints 220
3.9.4 Impact on the Market 222
3.9.5 Forecasts 223
3.9.6 Future Impact 229
3.10 Russia 230
3.10.1 Market Size 230
3.10.2 Drivers and Restraints 236
3.10.3 Impact on the Market 238
3.10.4 Forecasts 239
3.10.5 Future Impact 245
3.11 India 246
3.11.1 Market Size 246
3.11.2 Drivers and Restraints 253
3.11.3 Impact on the Market 255
3.11.4 Forecasts 256
3.11.5 Future Impact 263
3.12 China 264
3.12.1 Market Size 264
3.12.2 Drivers and Restraints 271
3.12.3 Impact on the Market 273
3.12.4 Forecasts 274
3.12.5 Future Impact 280
3.13 Key Takeaway 280
4 Ovarian Cancer Therapeutics - Opportunity and Unmet Need 281
4.1 Unmet Need 281
4.2 First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 282
4.3 Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 283
4.4 Key Takeaway 283
5 Ovarian Cancer Therapeutics - Competitive Assessment 284
5.1 Strategic Competitor Assessment 284
5.1.1 Benchmarking 284
5.1.2 Current Competitor Assessment 292
5.1.3 Chemotherapy 293
6 Ovarian Cancer Therapeutics - Strategic Assessment 294
6.1 Key Events Impacting the Future Market 294
6.2 Market Impact Analysis 295
6.3 Future Market Scenario 296
7 Product Profiles for the Major Marketed Products in the Ovarian Cancer Market 297
7.1.1 Carboplatin 297
7.1.2 Cisplatin 304
7.1.3 Paclitaxel 308
7.1.4 Altretamine 314
7.1.5 Hycamtin (topotecan hydrochloride) 317
7.1.6 Gemzar (gemcitabine) 322
7.1.7 Yondelis (trabectedin) 326
7.1.8 Doxil (doxorubicin Hcl liposome injection) 331
7.2 Partners in Commercialization 336
7.2.1 Taj Pharmaceuticals Enters Into License Agreement with AstraZeneca Pharmaceuticals for Gemcitabine HCI 336
7.2.2 APP Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical for Gemcitabine HCI 336
7.3 Key Takeaway 336
8 Ovarian Cancer - Pipeline Assessment 337
8.1 Overview 337
8.2 Pipeline Analysis by Phase of Development 337
8.3 Pipeline by Mechanism of Action 338
8.4 Pipeline by Line of Therapy 339
8.5 Strategic Pipeline Assessment 340
8.5.1 Technology Trends Analytic Framework 340
8.6 Ovarian Cancer Pipeline – Pipeline by Clinical Phases of Development 342
8.6.1 Ovarian Cancer – Pre-Registration Clinical Pipeline 342
8.6.2 Ovarian Cancer – Phase III of the Clinical Pipeline 343
8.6.3 Ovarian Cancer – Phase II of the Clinical Pipeline 344
8.6.4 Ovarian Cancer – Phase I of the Clinical Pipeline 348
8.6.5 Ovarian Cancer – Preclinical Pipeline 350
8.6.6 Ovarian Cancer – Discovery Stage Pipeline 351
8.7 Most Promising Drug Profiles 351
8.7.1 Avastin (bevacizumab) 351
8.7.2 Paclical (paclitaxel) 354
8.7.3 Votrient (pazopanib) 355
8.7.4 Farletuzumab (MORAb-003) 357
8.7.5 Karenitecin (BNP 1350) 359
8.7.6 Opaxio (xyotax, CT-2103) 361
8.7.7 AMG 386 364
8.7.8 EC-145 365
8.7.9 Recentin (cediranib, AZD2171) 367
8.7.10 Vargatef (BIBF 1120) 368
8.8 Partners in Research and Development 370
8.8.1 Licensing Agreements 370
8.8.2 Co-development Agreements 372
8.9 Key Takeaway 375
9 Ovarian Cancer Therapeutics - Clinical Trials Mapping 376
9.1 Clinical Trials 376
9.1.1 Clinical Trials by Status 376
9.1.2 Clinical Trials by Country 377
9.1.3 Clinical Trials by Phase 378
9.1.4 Clinical Trials by Sponsor Type 379
9.1.5 Clinical Trials – Leading Sponsors 380
9.1.6 Clinical Trials – Leading Company Sponsors by Phase 381
9.2 Patient Recruitment 382
10 Ovarian Cancer Therapeutics - Future Market Players 383
10.1 F. Hoffmann-La Roche Ltd. 383
10.1.1 Business Description 383
10.1.2 Financial Overview 383
10.1.3 SWOT Analysis 384
10.2 Menarini Group 389
10.2.1 Business Description 389
10.2.2 Financial Overview 389
10.2.3 SWOT Analysis 390
10.3 GlaxoSmithKline plc. 394
10.3.1 Business Description 394
10.3.2 Financial Overview 394
10.3.3 SWOT Analysis 395
10.4 Eisai Inc., 400
10.4.1 Business Description 400
10.4.2 Financial Overview 401
10.4.3 SWOT Analysis 401
10.5 Cell Therapeutics, Inc. 404
10.5.1 Business Description 404
10.5.2 Financial Overview 404
10.5.3 SWOT Analysis 405
10.6 Amgen Inc. 408
10.6.1 Business Description 408
10.6.2 Financial Overview 409
10.6.3 SWOT Analysis 410
10.7 AstraZeneca PLC 414
10.7.1 Business Description 414
10.7.2 Financial Overview 415
10.7.3 SWOT Analysis 415
10.8 Boehringer Ingelheim GmbH 419
10.8.1 Business Description 419
10.8.2 Financial Overview 419
10.8.3 SWOT Analysis 420
10.9 Oasmia Pharmaceutical AB 424
10.9.1 Business Description 424
10.9.2 Financial Overview 424
10.10 Endocyte, Inc. 424
10.10.1 Business Description 424
10.11 BioNumerik Pharmaceuticals, Inc. 424
10.11.1 Business Description 424
11 Ovarian Cancer Therapeutics - M&A Analysis 425
11.1 Key Highlights 425
11.1.1 M&A Agreements by Phase of Development 425
12 Ovarian Cancer Therapeutics - Expert Opinion 427
12.1 Important Data and Analysis from Key Opinion Leaders (KOLs) 427
12.1.1 Treatment Options (Surgery/Chemotherapy) 427
12.1.2 Treatment Options by Stage 427
12.1.3 Number of Chemotherapy Cycles 428
12.1.4 Future Therapies for Ovarian Cancer Treatment 428
12.1.5 Future Growth Rate of the Ovarian Cancer Market 428
12.1.6 Current Unmet Needs for Ovarian Cancer Treatment 428
12.1.7 What Ideal Features are Required in a New Drug 428
12.1.8 Past Patient Trends in Ovarian Cancer 428
12.1.9 Referral Pathway 428
13 Ovarian Cancer Therapeutics - Appendix 429
13.1 Definitions 429
13.2 Acronyms 429
13.3 Research Methodology 432
13.3.1 Coverage 433
13.3.2 Secondary Research 433
13.3.3 Forecasting 433
13.3.4 Primary Research 435
13.3.5 Expert Panel Validation 436
13.4 Contact Us 436
13.5 Disclaimer 436
13.6 Sources 436

List of Tables
1.1 List of Tables
Table 1: Ovarian Cancer, AJCC TNM and FIGO Staging System 17
Table 2: Ovarian Cancer, Classification and Treatment Protocol Stages 18
Table 3: Ovarian Cancer Stages I, II & III 20
Table 4: Ovarian Cancer Stage IV 21
Table 5: Ovarian Cancer, Classification of Ovarian Cancer, 2011 27
Table 6: Ovarian Cancer Five-Year Survival Rates 27
Table 7: Ovarian Cancer Chemotherapy Regimens 32
Table 8:Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36
Table 9: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38
Table 10: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 40
Table 11: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41
Table 12: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45
Table 13: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 47
Table 14: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48
Table 15: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50
Table 16: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 52
Table 17: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002–2011 54
Table 18: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2011–2020 55
Table 19: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56
Table 20: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58
Table 21: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2002–2011 60
Table 22: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61
Table 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 66
Table 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68
Table 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2011–2020 70
Table 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71
Table 27: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002–2011 73
Table 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2011–2020 74
Table 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76
Table 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78
Table 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2002–2011 80
Table 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82
Table 33: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2011–2020 87
Table 34: Ovarian Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011–2020 89
Table 35: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2011–2020 91
Table 36: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011–2020 93
Table 37: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002–2011 96
Table 38: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2011–2020 97
Table 39: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2002–2011 99
Table 40: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002–2011 101
Table 41: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 2002–2011 103
Table 42: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2002–2011 105
Table 43: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2011–2020 110
Table 44: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011–2020 112
Table 45: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 2011–2020 114
Table 46: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011–2020 116
Table 47: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002–2011 119
Table 48: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011–2020 120
Table 49: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2002–2011 122
Table 50: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002–2011 124
Table 51: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2002–2011 126
Table 52: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2002–2011 128
Table 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2011–2020 132
Table 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011–2020 134
Table 55: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2011–2020 136
Table 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138
Table 57: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2011 141
Table 58: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2011–2020 142
Table 59: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144
Table 60: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146
Table 61: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2002–2011 148
Table 62: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150
Table 63: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155
Table 64: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157
Table 65: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2011–2020 159
Table 66: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161
Table 67: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002–2011 164
Table 68: Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011–2020 165
Table 69: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167
Table 70: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169
Table 71: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2002–2011 171
Table 72: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173
Table 73: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178
Table 74: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180
Table 75: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2011–2020 182
Table 76: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184
Table 77: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002–2011 187
Table 78: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011–2020 188
Table 79: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190
Table 80: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192
Table 81: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2002–2011 194
Table 82: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196
Table 83: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201
Table 84: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203
Table 85: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2011–2020 205
Table 86: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207
Table 87: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002–2011 210
Table 88: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2011–2020 211
Table 89: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213
Table 90: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215
Table 91: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume, 2002–2011 216
Table 92: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218
Table 93: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223
Table 94: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225
Table 95: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume , 2011–2020 226
Table 96: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228
Table 97: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230
Table 98: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231
Table 99: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232
Table 100: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234
Table 101: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2011–2020 239
Table 102: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011–2020 240
Table 103: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2011–2020 241
Table 104: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011–2020 243
Table 105: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2002–2011 246
Table 106: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2002–2011 248
Table 107: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2002–2011 249
Table 108: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2002–2011 251
Table 109: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2011–2020 256
Table 110: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2020 258
Table 111: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2011–2020 259
Table 112: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011–2020 261
Table 113: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2002–2011 264
Table 114: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2002–2011 266
Table 115: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2002–2011 267
Table 116: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2002–2011 269
Table 117: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2011–2020 274
Table 118: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011–2020 276
Table 119: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2011–2020 277
Table 120: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011–2020 279
Table 121: Ovarian Cancer, Global, Clinical Endpoints – Approved Drugs, 2011 284
Table 122:Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, First-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285
Table 123: Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, Second-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285
Table 124:Ovarian Cancer Therapeutics , Global, Safety Profile of Approved Treatment in Loco-Regional and Advanced/Metastatic Setting, 2011 292
Table 125:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects NCIC Study, 2011 298
Table 126:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects SWOG Study, 2011 299
Table 127:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overview of Pivotal Trials, 2011 300
Table 128:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Progression Free Survival, 2011 301
Table 129: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overall Survival, 2011 301
Table 130:Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Incidence of Adverse Effects in the First-Line Treatment, 2011 309
Table 131:Ovarian Cancer Therapeutics Market, Global, Paclitaxel Incidence of Adverse Effects in the Second-Line Treatment, 2011 310
Table 132:Ovarian Cancer Therapeutics Market, Global, Altretamine, Incidence of Adverse Effects, 2011 315
Table 133:Ovarian Cancer Therapeutics, Hycamtin, Incidence of Adverse Effects, 2011 318
Table 134: Ovarian Cancer Therapeutics , Gemzar, Incidence of Adverse Effects, 2011 323
Table 135:Ovarian Cancer Therapeutics Market, Global, Yondelis, Incidence of Adverse Effects, 2011 327
Table 136: Ovarian Cancer Therapeutics Market, Global, Doxil, Incidence of Adverse Effects, 2011 332
Table 137: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339
Table 138: Ovarian Cancer Pipeline, Pre-Registration, 2011 342
Table 139: Ovarian Cancer Pipeline, Phase III, 2011 343
Table 140: Ovarian Cancer Pipeline, Phase II, 2011 344
Table 141: Ovarian Cancer Pipeline, Phase I, 2011 348
Table 142: Ovarian Cancer Pipeline, Prelinical, 2011 350
Table 143: Ovarian Cancer Pipeline, Discovery, 2011 351
Table 144: Ovarian Cancer, Global, Licensing Agreements, 2009–2011 372
Table 145: Ovarian Cancer, Global, Co-development Agreements, 2009–2011 374
Table 146: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376
Table 147: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377
Table 148: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378
Table 149:Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379
Table 150:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380
Table 151:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011 381
Table 152:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, March 2011 382
Table 153: Ovarian Cancer, Global, M&A Deals by Geography, 2009–2011 426
Table 154: Ovarian Cancer Therapeutics Market, Global, Treatment Options by Stage, 2011 427

List of Figures
1.2 List of Figures
Figure 1: Ovarian Cancer, Treatment Algorithm, Stage I and II 31
Figure 2: Ovarian Cancer, Treatment Algorithm, Stage III and IV 31
Figure 3: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2002–2011 34
Figure 4: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36
Figure 5: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38
Figure 6: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 39
Figure 7: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41
Figure 8: Ovarian Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2011 42
Figure 9: Ovarian Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011 44
Figure 10: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45
Figure 11: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2011–2020 46
Figure 12: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48
Figure 13: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50
Figure 14: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020 52
Figure 15: Ovarian Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2011–2020 53
Figure 16: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002-2020 54
Figure 17: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56
Figure 18: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58
Figure 19: Ovarian Cancer Therapeutics Market, The US, Patient Volume (absolute), 2002–2011 60
Figure 20: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61
Figure 21: Ovarian Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2011 63
Figure 22: Ovarian Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011 65
Figure 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 66
Figure 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68
Figure 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume (Absolute), 2011–2020 70
Figure 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71
Figure 27: Ovarian Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2011–2020 72
Figure 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002-2020 73
Figure 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76
Figure 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78
Figure 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 2002–2011 80
Figure 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82
Figure 33: Ovarian Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2011 84
Figure 34: Ovarian Cancer Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011 86
Figure 35: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2011–2020 87
Figure 36: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011–2020 89
Figure 37: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 2011–2020 91
Figure 38: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011–2020 93
Figure 39: Ovarian Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011–2020 95
Figure 40: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002-2020 96
Figure 41: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2002–2011 99
Figure 42: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002–2011 101
Figure 43: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2002–2011 103
Figure 44: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2002–2011 105
Figure 45: Ovarian Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2011 107
Figure 46: Ovarian Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011 109
Figure 47: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2011–2020 110
Figure 48: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011–2020 112
Figure 49: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2011–2020 114
Figure 50: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011–2020 116
Figure 51: Ovarian Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011–2020 118
Figure 52: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 119
Figure 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2002–2011 122
Figure 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002–2011 124
Figure 55: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 2002–2011 126
Figure 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2002–2011 128
Figure 57: Ovarian Cancer Therapeutics Market, France, Market Drivers and Restraints, 2011 130
Figure 58: Ovarian Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2011 131
Figure 59: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2011–2020 132
Figure 60: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011–2020 134
Figure 61: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 2011–2020 136
Figure 62: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138
Figure 63: Ovarian Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2011–2020 140
Figure 64: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2020 141
Figure 65: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144
Figure 66: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146
Figure 67: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2002–2011 148
Figure 68: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150
Figure 69: Ovarian Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2011 152
Figure 70: Ovarian Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011 154
Figure 71: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155
Figure 72: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157
Figure 73: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2011–2020 159
Figure 74: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161
Figure 75: Ovarian Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011–2020 163
Figure 76: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 164
Figure 77: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167
Figure 78: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169
Figure 79: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2002–2011 171
Figure 80: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173
Figure 81: Ovarian Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2011 175
Figure 82: Ovarian Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011 177
Figure 83: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178
Figure 84: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180
Figure 85: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2011–2020 182
Figure 86: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184
Figure 87: Ovarian Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011–2020 186
Figure 88: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 187
Figure 89: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190
Figure 90: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192
Figure 91: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2002–2011 194
Figure 92: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196
Figure 93: Ovarian Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2011 198
Figure 94: Ovarian Cancer Therapeutics Market, Japan, Impact of Historical Events on the Market, 2011 200
Figure 95: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201
Figure 96: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203
Figure 97: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2011–2020 205
Figure 98: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207
Figure 99: Ovarian Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011–2020 209
Figure 100: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 210
Figure 101: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213
Figure 102: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215
Figure 103: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2002–2011 216
Figure 104: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218
Figure 105: Ovarian Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 220
Figure 106: Ovarian Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 222
Figure 107: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223
Figure 108: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225
Figure 109: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2011–2020 226
Figure 110: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228
Figure 111: Ovarian Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011–2020 229
Figure 112: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230
Figure 113: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231
Figure 114: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232
Figure 115: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234
Figure 116: Ovarian Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2011 236
Figure 117: Ovarian Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2011 238
Figure 118: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2011–2020 239
Figure 119: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011–2020 240
Figure 120: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2011–2020 241
Figure 121: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011–2020 243
Figure 122: Ovarian Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011–2020 245
Figure 123: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2002–2011 246
Figure 124: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2002–2011 248
Figure 125: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2002–2011 249
Figure 126: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2002–2011 251
Figure 127: Ovarian Cancer Therapeutics Market, India, Market Drivers and Restraints, 2011 253
Figure 128: Ovarian Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2011 255
Figure 129: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2011–2020 256
Figure 130: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2020 258
Figure 131: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2011–2020 259
Figure 132: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011–2020 261
Figure 133: Ovarian Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 2011–2020 263
Figure 134: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2002–2011 264
Figure 135: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2002–2011 266
Figure 136: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2002–2011 267
Figure 137: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2002–2011 269
Figure 138: Ovarian Cancer Therapeutics Market, China, Market Drivers and Restraints, 2011 271
Figure 139: Ovarian Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2011 273
Figure 140: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2011–2020 274
Figure 141: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011–2020 276
Figure 142: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2011–2020 277
Figure 143: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011–2020 279
Figure 144: Ovarian Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 2011–2020 280
Figure 145: Ovarian Cancer, Global, Opportunity and Unmet Need in First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting, 2011 282
Figure 146: Ovarian Cancer, Global, Opportunity and Unmet Need in Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting, 2011 283
Figure 147: Ovarian Cancer, Global, Response Rate in First-Line Loco-Regional and Advanced/Metastatic Setting, (%), 2011 285
Figure 148: Ovarian Cancer, Global, Overall Survival in First-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 286
Figure 149: Ovarian Cancer, Global, Progression-free Survival in First-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 287
Figure 150: Ovarian Cancer, Global, Response Rate in Second-Line Loco-Regional and Advanced/Metastatic Setting, (%) 2011 288
Figure 151: Ovarian Cancer, Global, Overall Survival in Second-Line Loco-Regional and Advanced/Metastatic Setting, (%), 2011 289
Figure 152: Ovarian Cancer, Global, Progression-Free Survival in Second-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 290
Figure 153: Ovarian Cancer, Global, Time-to-Progression in Second-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 291
Figure 154: Strategic Competitor Assessment of the Marketed Chemotherapy Products for Ovarian Cancer, 2011 293
Figure 155: Ovarian Cancer, Global, Key Events Impacting the Future Market, 2011 294
Figure 156: Ovarian Cancer, Global, Implications for Future Market Competition, 2011 296
Figure 157: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Chemical Structure, 2011 297
Figure 158: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Sales Forecast ($m), 2002-2020 302
Figure 159: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Market Share Analysis (%), 2011 303
Figure 160: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Chemical Structure, 2011 304
Figure 161: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Sales Forecast ($m), 2002–2020 306
Figure 162: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Market Share Analysis (%), 2011 307
Figure 163: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Chemical Structure, 2011 308
Figure 164: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Life Cycle Management Activities, 2011 311
Figure 165: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Sales Forecast ($m), 2002-2015 312
Figure 166: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Market Share Analysis (%), 2011 313
Figure 167: Ovarian Cancer Therapeutics Market, Global, Altretamine, Chemical Structure, 2011 314
Figure 168: Ovarian Cancer Therapeutics Market, Global, Altretamine, Life Cycle Management Activities, 2011 316
Figure 169: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Chemical Structure, 2011 317
Figure 170: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Life Cycle Management Activities, 2011 319
Figure 171: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Sales Forecast ($m), 2002–2015 320
Figure 172: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Market Share Analysis (%), 2011 321
Figure 173: Ovarian Cancer Therapeutics Market, Global, Gemzar, Chemical Structure, 2011 322
Figure 174: Ovarian Cancer Therapeutics Market, Global, Gemzar, Life Cycle Management Activities, 2011 324
Figure 175: Ovarian Cancer Therapeutics Market, Global, Gemzar, Sales Forecast ($m), 2004–2015 325
Figure 176: Ovarian Cancer Therapeutics Market, Global, Gemzar, Market Share Analysis (%), 2011 326
Figure 177: Ovarian Cancer Therapeutics Market, Global, Yondelis, Chemical Structure, 2011 327
Figure 178: Ovarian Cancer Therapeutics Market, Global, Yondelis, Life Cycle Management Activities, 2011 329
Figure 179: Ovarian Cancer Therapeutics Market, Global, Yondelis, Sales Forecast ($m), 2009–2020 329
Figure 180: Ovarian Cancer Therapeutics Market, Global, Yondelis, Market Share Analysis (%), 2011 330
Figure 181: Ovarian Cancer Therapeutics Market, Global, Doxil, Chemical Structure, 2011 331
Figure 182: Ovarian Cancer Therapeutics Market, Global, Doxil, Life Cycle Management Activities, 2011 333
Figure 183: Ovarian Cancer Therapeutics Market, Global, Doxil, Sales Forecast ($m), 2002-2016 334
Figure 184: Ovarian Cancer Therapeutics Market, Global, Doxil, Market Share Analysis (%), 2011 335
Figure 185: Ovarian Cancer, Global, Clinical Trials by Phase of Development, 2011 337
Figure 186: Ovarian Cancer, Global, Pipeline by Mechanism of Action, 2011 338
Figure 187: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339
Figure 188: Ovarian Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 341
Figure 189: Ovarian Cancer, Global, Technology Trends Description of Pipeline Drugs, 2011 341
Figure 190: Ovarian Cancer Pipeline by Phase of Clinical Development, 2011 342
Figure 191: Ovarian Cancer Therapeutics Market, Global, Avastin Sales Forecasts ($m), 2012-2020 353
Figure 192: Ovarian Cancer Therapeutics Market, Global, Paclical Sales Forecast ($m), 2012–2020 355
Figure 193: Ovarian Cancer Therapeutics Market, Global, Votrient Sales Forecast ($m), 2013–2020 357
Figure 194: Ovarian Cancer Therapeutics Market, Global, Farletuzumab Sales Forecast ($m), 2014-2020 359
Figure 195: Ovarian Cancer Therapeutics Market, Global, Karenitecin Sales Forecast ($m), 2014-2020 361
Figure 196: Ovarian Cancer Therapeutics Market, The US, Opaxio Sales Forecast ($m), 2014-2020 363
Figure 197: Ovarian Cancer Therapeutics Market, Global, AMG 386 Sales Forecast ($m), 2015–2020 365
Figure 198: Ovarian Cancer Therapeutics Market, Global, EC145 Sales Forecast ($m), 2016–2020 366
Figure 199: Ovarian Cancer Therapeutics Market, Global, Recentin Sales Forecast ($m), 2015–2020 368
Figure 200: Ovarian Cancer Therapeutics Market, Global, Vargatef Sales Forecast ($m), 2017-2020 370
Figure 201: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376
Figure 202: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377
Figure 203: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378
Figure 204: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379
Figure 205: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380
Figure 206: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011 381
Figure 207: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, March 2011 382
Figure 208: Ovarian Cancer, F. Hoffmann-La Roche Ltd., SWOT Analysis 2011 384
Figure 209: Ovarian Cancer, Menarini Group, SWOT Analysis 2011 390
Figure 210: Ovarian Cancer, Global, GlaxoSmithKline, SWOT Analysis 2011 395
Figure 211: Ovarian Cancer, Eisai Inc., SWOT Analysis 2011 401
Figure 212: Ovarian Cancer, Cell Therapeutics, Inc., SWOT Analysis 2011 405
Figure 213: Ovarian Cancer, Amgen Inc., SWOT Analysis 2011 410
Figure 214: Ovarian Cancer, Global, AstraZeneca, SWOT Analysis 2011 415
Figure 215: Ovarian Cancer, Boehringer Ingelheim GmbH, SWOT Analysis 2011 420
Figure 216: Ovarian Cancer, Global, Key Data Inputs from KOL Interviews, 2011 427
Figure 217: GlobalData Market Forecasting Model 435